Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Awakn Life Sciences Corp C.AWKN

Alternate Symbol(s):  AWKNF

Healthcare Psychedelics
Awakn Life Sciences Corp. is a Canada-based clinical-stage biotechnology company. The Company is developing therapeutics for substance use and mental health disorders, with a near-term focus on alcohol use disorder (AUD). The Company's therapeutics are focused on the brain circuits that drive addiction. The Company operates through three segments: development, delivery and corporate. The... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (CSE:AWKN)

Awakn Life Sciences Announces Shareholder Approval of Arrangement

Newsfile April 23, 2025

Awakn Life Sciences Provides Supplemental Disclosure in Connection with Proposed Plan of Arrangement

Newsfile April 11, 2025

Awakn Life Sciences Enters into Arrangement Agreement for The Acquisition of Awakn by Solvonis Therapeutics plc

Newsfile February 27, 2025

Awakn Life Sciences Provides Update on R&D Programs, Progressing Novel Therapeutics for Alcohol Use Disorder and PTSD

Newsfile January 27, 2025

Awakn Announces Positive Outcome of Pre-IND Meeting with FDA for AWKN-002 in Alcohol Use Disorder

Newsfile January 20, 2025

Awakn Life Sciences Announces Credit Facility

Newsfile December 18, 2024

Canadian Investment Regulatory Organization Trading Halt - AWKN

Canada NewsWire December 16, 2024

Awakn Life Sciences Enters into Binding Letter of Intent for Acquisition of Awakn by Graft Polymer (UK) Plc

Newsfile December 16, 2024

Awakn Announces Promising Results from Aminoindane New Chemical Entity Pre-Clinical Program

Newsfile December 10, 2024
View More News ››

Opinion & Analysis (CSE:AWKN)

No current opinion is available.
View More Opinion ››

Bullboard Posts (CSE:AWKN)

Approval

Tech, April 23, 2025  - Solvonis acquisition of Awakn wins overwhelming backing from shareholders. Solvonis secured more than 99...
TheBridge - April 29, 2025

RE:One Step Closer

And, it appears....Two Steps Farther Away. Wed. April 16, 2025 - "Solvonis shares fall with "high risk" that losses will...
TheBridge - April 22, 2025

One Step Closer

Source: Tech - March 18, 2025 SVNS has provided an update on it's AWKN-SDN-14 programme, a project aimed at developing a next...
TheBridge - March 25, 2025

Significant

In an announcement on March 11, 2025, Solvonis Therapeutics PLC announced that they had appointed Dr. Renata Crome as its new independent...
TheBridge - March 17, 2025

Latest Info

Solvonis Therapeutics lays out roadmap for Awakn Life Sciences acquisiton. (Feb. 24, 2025) - SVNS has formalized its plans to acqure...
TheBridge - February 24, 2025

Update Again

Just in case you're interested. In a January 14, 2025 announcement Graft Polymer became Solvonis Therapeutics, saying that the change...
TheBridge - February 4, 2025
View more Bullboard ››

Tidal Care Inc.

Tidal Care Inc.

Tidal Care aims to be a high-compliance supplier of finished, formulated Psilocybin- and MDMA-based drug products to the ...
View More »